A Deloitte partner has been barred from the profession for two years, and the
firm given a $1m (£480,000) penalty over its audit of Ligand Pharmaceuticals in
Public Company Accounting Oversight Board yesterday issued orders against
the firm and the former audit partner, James L. Fazio, for breach of the board’s
interim auditing standards.
The audit had failed to properly assess the company’s accounting for product
returns, the body said.
‘Mr. Fazio failed to perform appropriate and adequate audit procedures
related to Ligand’s reported revenue from sales of products for which a right of
return existed and failed to supervise others adequately to ensure the
performance of such procedures.,’ the PCAOB said in a statement.
‘In evaluating the reasonableness of Ligand’s estimates of future returns,
Mr. Fazio neither performed nor ensured the performance of procedures that
adequately took into account the extent to which Ligand had consistently and
substantially underestimated its product returns,’ it added.
Fazio cannot become an ‘associated person’ of a registered PCAOB accounting
firm for two years, when he may reapply to the board, it said.
The firm, without admitting or denying the board’s finding, consented to a
$1m penalty. It has also implemented changes to its practices and will carry out
further improvements to the way it documents quality control, the board said.
The second largest improvement in ‘significant’ levels of financial distress since the EU Referendum was in professional services, found research from Begbies Traynor
Two new audit partners have been appointed at the firm BDO in its audit practice following continued growth and investment
Investment in people, tech and businesses impacts on EY's profit per partner figure
If businesses do not take cyber security seriously in their business planning regulators may do it for them, the ICAEW has warned